Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Vascular Endothelial Growth Inhibitor 174 Is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma

LIYANG WU, XIAOBEI LI, LIN YE, DUOERKUN SHAYIREMU, XIAOHU DENG, XIAODONG ZHANG, WENGUO JIANG, YONG YANG, KAN GONG and NING ZHANG
Anticancer Research February 2014, 34 (2) 715-722;
LIYANG WU
1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XIAOBEI LI
1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIN YE
2Cardiff University-Capital Medical University Joint Centre for Biomedical Research, Cardiff University School of Medicine, Cardiff, U.K.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DUOERKUN SHAYIREMU
3Department of Urology, Central Hospital of Hami, Hami, Xinjiang Uygur Autonomous Region, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XIAOHU DENG
4Department of Surgery, People's Hospital of Karamay, Xinjiang Uygur Autonomous Region, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
XIAODONG ZHANG
1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WENGUO JIANG
2Cardiff University-Capital Medical University Joint Centre for Biomedical Research, Cardiff University School of Medicine, Cardiff, U.K.
5Cardiff University-Capital Medical University Joint Centre for Biomedical Research and Cancer Institute, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YONG YANG
6Department of Urological Oncology, Peking University Cancer Hospital, Haidian District, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KAN GONG
7Department of Urology, Peking University First Hospital, Xicheng District, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: niru7429@126.com gongkan2004@yahoo.com.cn
NING ZHANG
1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China
5Cardiff University-Capital Medical University Joint Centre for Biomedical Research and Cancer Institute, Capital Medical University, Beijing, P.R. China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: niru7429@126.com gongkan2004@yahoo.com.cn
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 34 no. 2 715-722
PubMed 
24511004

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received December 5, 2013
  • Revision received December 21, 2013
  • Accepted December 23, 2013
  • Published online February 7, 2014.

Copyright & Usage 
Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. LIYANG WU1,*,
  2. XIAOBEI LI1,*,
  3. LIN YE2,
  4. DUOERKUN SHAYIREMU3,
  5. XIAOHU DENG4,
  6. XIAODONG ZHANG1,
  7. WENGUO JIANG2,5,
  8. YONG YANG6,
  9. KAN GONG7⇑ and
  10. NING ZHANG1,5⇑
  1. 1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, P.R. China
  2. 2Cardiff University-Capital Medical University Joint Centre for Biomedical Research, Cardiff University School of Medicine, Cardiff, U.K.
  3. 3Department of Urology, Central Hospital of Hami, Hami, Xinjiang Uygur Autonomous Region, P.R. China
  4. 4Department of Surgery, People's Hospital of Karamay, Xinjiang Uygur Autonomous Region, P.R. China
  5. 5Cardiff University-Capital Medical University Joint Centre for Biomedical Research and Cancer Institute, Capital Medical University, Beijing, P.R. China
  6. 6Department of Urological Oncology, Peking University Cancer Hospital, Haidian District, Beijing, P.R. China
  7. 7Department of Urology, Peking University First Hospital, Xicheng District, Beijing, P.R. China
  1. Correspondence to: Ning Zhang, MD, Ph.D., Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, No. 8, Gongti South Road, Chaoyang District, Beijing 100020, P.R. China. Tel: +86 1085231457, Fax: +86 1085231802, e-mail: niru7429{at}126.com or Kan Gong, Department of Urology, Peking University First Hospital, Xicheng District, Beijing, P.R. China. E-mail: gongkan2004{at}yahoo.com.cn
View Full Text

Cited By...

  • 13 Citations
  • Google Scholar
PreviousNext
Back to top

In this issue

Anticancer Research: 34 (2)
Anticancer Research
Vol. 34, Issue 2
February 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vascular Endothelial Growth Inhibitor 174 Is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
3 + 7 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Vascular Endothelial Growth Inhibitor 174 Is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma
LIYANG WU, XIAOBEI LI, LIN YE, DUOERKUN SHAYIREMU, XIAOHU DENG, XIAODONG ZHANG, WENGUO JIANG, YONG YANG, KAN GONG, NING ZHANG
Anticancer Research Feb 2014, 34 (2) 715-722;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Vascular Endothelial Growth Inhibitor 174 Is a Negative Regulator of Aggressiveness and Microvascular Density in Human Clear Cell Renal Cell Carcinoma
LIYANG WU, XIAOBEI LI, LIN YE, DUOERKUN SHAYIREMU, XIAOHU DENG, XIAODONG ZHANG, WENGUO JIANG, YONG YANG, KAN GONG, NING ZHANG
Anticancer Research Feb 2014, 34 (2) 715-722;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Protein of Vascular Endothelial Growth Inhibitor 174 Inhibits Epithelial-Mesenchymal Transition in Renal Cell Carcinoma In Vivo
  • Identification of Novel Proteins Interacting with Vascular Endothelial Growth Inhibitor 174 in Renal Cell Carcinoma
  • Estimation of the Six-month Survival Probability After Radiosurgery for Brain Metastases from Kidney Cancer
  • Google Scholar

More in this TOC Section

  • Effect of Chloroquine on Doxorubicin-induced Apoptosis in A549 Cells
  • Effect of Aspirin on G0/G1 Cell Cycle Arrest and microRNA Signatures in Pancreatic Adenocarcinoma Cells
  • Suppression of Inflammatory Cytokine Genes Expression in Vascular Endothelial Cells by Super-low Dose Lipopolysaccharide-activated Macrophages
Show more Experimental Studies

Similar Articles

Keywords

  • Vascular endothelial growth inhibitor 174 (VEGI 174)
  • microvessel density (MVD)
  • prognosis
  • Clear cell renal cell carcinoma
Anticancer Research

© 2022 Anticancer Research

Powered by HighWire